Application Note: Proteomic plasma biomarkers for predicting response and resistance with immune checkpoint inhibitors in cancer patients
6 November 2020

In this study, Olink Proteomics demonstrates how comprehensive proteomic profiling can enable the discovery of important immune and tumor changes associated with response or non-response to checkpoint blockade, and how plasma-based biomarkers can allow the identification of baseline predictive biomarkers for response to immunotherapy.